Epizyme's Tazemetostat Shows Promise in Follicular Lymphoma Trial
Stage 1 of the trial assessing Tazemetostat in combination with Lenalidomide and Rituximab has been completed, focusing on safety and tolerability.
Asset / Drug
Drug and asset intelligence for Tazemetostat with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.